Drug Profile
QAL 964
Alternative Names: QAL-964Latest Information Update: 05 Sep 2017
Price :
$50
*
At a glance
- Originator Novartis
- Class Antirheumatics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 16 May 2015 Novartis terminates phase II trial in Rheumatoid arthritis in Hungary and Greece (PO) (EudraCT2013-003493-27)
- 08 Apr 2014 Phase-II clinical trials in Rheumatoid arthritis in Hungary (PO)